We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
- Authors
Monforte, Antonella d'Arminio; Cozzi-Lepri, Alessandro; Biagio, Antonio Di; Marchetti, Giulia; Caputo, Sergio Lo; Rusconi, Stefano; Gianotti, Nicola; Mazzotta, Valentina; Mazzarello, Giovanni; Costantini, Andrea; Castagna, Antonella; Antinori, Andrea; d'Arminio Monforte, Antonella; Di Biagio, Antonio; Lo Caputo, Sergio; ICONA Foundation Study Group
- Abstract
<bold>Objectives: </bold>To evaluate the durability of three integrase strand transfer inhibitors (INSTIs) and two NRTIs in ART-naive individuals.<bold>Methods: </bold>The study design was observational. Patients were HIV-positive, ART-naive subjects starting raltegravir, elvitegravir/cobicistat or dolutegravir with two NRTIs. The primary endpoint was time to treatment failure, i.e. occurrence of virological failure (first of two consecutive plasma HIV RNAs ≥200 copies/mL after 24 weeks) or INSTI discontinuation for any reason apart from simplification. Secondary endpoints were INSTI discontinuation due to toxicity/intolerance and CD4 count response. Survival analysis was done using Kaplan-Meier and Cox regression.<bold>Results: </bold>Two thousand and sixteen patients were included: 310 (15.4%) started raltegravir-based regimens, 994 (49.3%) started dolutegravir-based regimens and 712 (35.3%) started elvitegravir/cobicistat-based regimens. Over a median of 11 months, 167 patients experienced treatment failure; the 1 year probability of treatment failure was 6.5% for raltegravir, 5.4% for dolutegravir and 6.7% for elvitegravir/cobicistat (P = 0.001). Sixty-eight patients (3.4%) discontinued INSTIs owing to toxicity/intolerance. By multivariable analysis, patients starting raltegravir had a 2.03-fold (95% CI = 1.2-3.2) higher risk and patients on elvitegravir/cobicistat a 1.88-fold (95% CI = 1.2-2.9) higher risk of treatment failure versus dolutegravir; there was no difference in risk of discontinuation due to toxicity/intolerance when comparing dolutegravir and raltegravir and marginal evidence for a difference when comparing elvitegravir/cobicistat and dolutegravir (adjusted relative hazard = 1.94 for elvitegravir/cobicistat versus dolutegravir, 95% CI = 1.00-3.76, P = 0.05).<bold>Conclusions: </bold>In our real-life setting, INSTI-based regimens showed high potency and durability. Among regimens currently recommended in Europe, those including dolutegravir are associated with a lower risk of treatment failure.
- Subjects
INTEGRASES; MULTIVARIABLE testing; ANTIRETROVIRAL agents; HIV infections; MEDICAL care
- Publication
Journal of Antimicrobial Chemotherapy (JAC), 2019, Vol 74, Issue 5, p1363
- ISSN
0305-7453
- Publication type
journal article
- DOI
10.1093/jac/dky566